CASI
CASI Pharmaceuticals Inc.
$1.39
-$0.05(-3.47%)
31
Overall
--
Value
18
Tech
44
Quality
Market Cap
$24.48M
Volume
17.19K
52W Range
$1.09 - $6.30
Target Price
$4.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $47.7K | -- | -- | -- | $4.1M | $15.1M | $30.2M | $43.1M | $33.9M | $28.5M | ||
| Total Revenue | $47.7K | -- | -- | -- | $4.1M | $15.1M | $30.2M | $43.1M | $33.9M | $28.5M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-6.3K | -- | -- | -- | $3.9M | $9.5M | $12.6M | $15.8M | $13.8M | $17.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $41.4K | -- | -- | $-687.0K | $128.0K | $5.6M | $17.6M | $27.3M | $20.1M | $11.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $7.2M | $9.4M | $10.8M | $26.8M | $46.7M | $56.8M | $59.4M | $53.8M | $45.5M | $50.5M | ||
| Research & Development | $4.1M | $4.6M | $7.6M | $8.5M | $16.3M | $29.3M | $21.0M | $16.0M | $9.9M | $8.9M | ||
| Research Expense | $4.1M | $4.6M | $7.6M | $8.5M | $16.3M | $29.3M | $21.0M | $16.0M | $9.9M | $8.9M | ||
| Selling, General & Administrative | $3.1M | $4.8M | $3.2M | $18.0M | $30.4M | $27.5M | $38.4M | $37.8M | $41.8M | $41.4M | ||
| Selling & Marketing Expenses | $-27.5K | -- | -- | -- | $3.1M | $7.8M | $14.7M | $14.3M | $16.4M | $17.9M | ||
| General & Administrative Expenses | $3.1M | $4.8M | $3.2M | $18.0M | $27.3M | $19.7M | $23.7M | $23.4M | $25.4M | $23.6M | ||
| Salaries & Wages | $-1.5M | $-3.0M | $-650.4K | $320.0K | $-7.3M | $7.8M | $7.8M | $7.0M | -- | -- | ||
| Depreciation & Amortization | $-68.4K | $-66.5K | $-117.8K | $-366.0K | $-603.0K | $562.0K | $500.0K | $1.2M | -- | -- | ||
| Depreciation & Amortization | $-27.5K | $6.8K | $19.9K | $-366.0K | $-603.0K | $562.0K | $500.0K | $1.2M | -- | -- | ||
| Amortization | $-75.0K | $-26.0K | $-7.0K | $-1.3M | $-1.6M | $1.3M | $12.2M | $1.2M | -- | -- | ||
| Securities Amortization | -- | -- | -- | -- | $1.1M | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-34.0K | $-35.0K | $-62.0K | $-2.0K | $-1.3M | -- | -- | -- | $-6.2M | $190.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-7.1M | $-9.4M | $-10.8M | $-27.5M | $-46.6M | $-51.5M | $-41.5M | $-26.5M | $-25.5M | $-39.4M | ||
| EBITDA | $-7.1M | $-9.4M | $-10.7M | $-25.8M | $-44.3M | $-31.4M | $-33.4M | $-35.1M | -- | -- | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | $-7.5K | $-7.5K | $3.0K | $-866.0K | $-321.0K | $-127.0K | -- | -- | ||
| Interest Income Operating | -- | -- | -- | -- | -- | -- | -- | -- | $629.0K | $539.0K | ||
| Net Non-Operating Interest Income/Expense | -- | -- | $7.5K | $7.5K | $-3.0K | $866.0K | $321.0K | $127.0K | $-614.0K | -- | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $-865.0K | $20.0K | -- | -- | ||
| Other Income/Expense | -- | -- | -- | -- | $615.0K | $-5.6M | $-5.3M | $6.4M | $-1.3M | $-478.0K | ||
| Other Special Charges | -- | -- | -- | -- | $73.0K | $1.2M | $558.0K | $44.0K | $764.0K | $188.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | $386.0K | $-1.5M | -- | $-8.7M | $-2.0M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $-386.0K | $1.5M | -- | $8.7M | $2.0M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-7.2M | $-9.4M | $-10.8M | $-27.5M | $-46.4M | $-33.3M | $-35.2M | $-37.6M | -- | -- | ||
| Pre-Tax Income | $-7.2M | $-9.4M | $-10.8M | $-27.5M | $-46.4M | $-47.5M | $-35.8M | $-38.3M | $-25.6M | $-39.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-837.0K | $6.8K | $-125.0K | -- | -- | $-732.0K | -- | $2.0M | $-81.0K | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-7.2M | $-9.5M | $-10.8M | $-27.5M | $-46.0M | $-48.3M | $-36.7M | $-41.0M | $-24.8M | $-39.3M | ||
| Net Income (Continuing Operations) | $-7.2M | $-9.5M | $-10.8M | $-27.5M | $-46.0M | $-48.3M | $-36.7M | $-41.0M | $-25.5M | $-39.3M | ||
| Net Income (Discontinued Operations) | $-7.2M | $-9.5M | $-10.8M | $-27.5M | $-46.0M | $-48.3M | $-36.7M | $-41.0M | $-24.8M | $-39.3M | ||
| Net Income (Common Stockholders) | $-7.2M | $-9.5M | $-10.8M | $-27.5M | $-46.0M | $-48.3M | $-36.7M | $-41.0M | $-24.8M | $-39.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-29.7M | $-25.2M | -- | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $7.2M | $9.4M | $10.8M | $26.8M | $50.7M | $66.3M | $71.9M | $69.6M | $59.4M | $67.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $3.2M | $5.6M | $6.2M | $8.5M | $959.5K | $1.1M | $1.4M | $13.6M | $13.4M | $15.3M | ||
| Average Shares Outstanding (Diluted) | $3.3M | $5.6M | $6.0M | $8.6M | $959 | $1.1K | $1.4M | $13.6M | $13.4M | $15.3M | ||
| Shares Outstanding | $425.8K | $602.0K | $796.4K | $957.2K | $990.2K | $1.4M | $1.4M | $13.5M | $15.5M | $15.5M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-44 | $-2.69 | $-3.01 | $-2.02 | $-2.56 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-44 | $-27 | $-3.01 | $-2.02 | $-2.56 | ||
| Diluted EPS | $-2.2 | $-1.7 | $-1.8 | $-3.2 | $-48 | $-44 | $-27 | $-3.01 | $-2.02 | $-2.56 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-48 | -- | $-27 | $-3.01 | $-2.02 | $-2.56 | ||
| OTHER METRICS | ||||||||||||
| Depletion | $-27.5K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | -- | $4.5M | $-48.0K | $-1.2M | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | -- | $4.5M | $-48.0K | $-1.2M | ||
| Fees | -- | -- | -- | $-320.1K | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $-400.0K | -- | $-65.0K | $-2.1M | -- | $479.0K | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | -- | -- | $15.0K | $871.0K | ||
| Marketing Expense | $-27.5K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | $395.0K | $-776.0K | $-812.0K | $8.7M | $701.0K | -- | ||
| Net Income From Other Gains Losses | -- | -- | -- | -- | -- | $1.7M | $1.5M | $9.5M | -- | -- | ||
| Net Operating Interest Income Expense | $-81.5K | $-26.1K | $1.0K | $40.0K | -- | -- | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $13.8M | $17.4M | ||
| Other Gand A | $3.1M | $4.8M | $3.2M | $18.0M | $27.3M | $19.7M | $23.7M | $23.4M | $25.4M | $23.6M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $-306.0K | $-1.5M | $-6.4M | -- | $696.0K | ||
| Rent And Landing Fees | $3.1M | $4.8M | $3.2M | $18.0M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | -- | -- | $3.1M | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $288.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CASI | $1.39 | -3.5% | 17.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get CASI Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW